GlassScriptPhysician profile
Michael L Pirics
NPI 1891926366
$3,558.41
in general payments reported to CMS, 2019-2025
39 companies · $314 in 2025
The $314 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $136 · 2020: $143 · 2021: $563 · 2022: $859 · 2023: $635 · 2024: $908 · 2025: $314.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,856.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,856.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $387.37 | 2020-2023 | |
| Merck Sharp & Dohme LLC | $324.91 | 2021-2025 | Keytruda, Lynparza |
| Astellas Pharma US INC | $292.35 | 2023-2024 | Veozah, Cresemba |
| Abbvie INC. | $248.14 | 2019-2024 | |
| Organon LLC | $173.86 | 2022-2024 | Nexplanon |
| Eisai INC. | $156.06 | 2022-2025 | |
| Myovant Sciences INC. | $152.13 | 2021-2022 | |
| Baxter Healthcare | $142.06 | 2024 | Perclot |
| Astrazeneca Pharmaceuticals LP | $136.99 | 2022-2025 | Lynparza |
| Therapeuticsmd, INC. | $128.03 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $119.94 | 2024 | |
| Hologic Sales and Service, LLC | $106.77 | 2019-2023 | Affirm Prone Biopsy System |
| Biotissue Holdings INC. | $100.71 | 2025 | |
| Daiichi Sankyo INC. | $80.65 | 2021-2023 | Injectafer |
| Exeltis, USA INC. | $76.17 | 2021-2022 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $70.90 | 2023 | Myfembree |
| Mayne Pharma Commercial LLC | $65.87 | 2022-2023 | |
| Avion Pharmaceuticals | $65.70 | 2019-2020 | |
| Pacira Pharmaceuticals Incorporated | $65.11 | 2021-2025 | Exparel |
| Evofem Biosciences, INC. | $63.36 | 2021-2022 | |
| Aspira Women'S Health INC | $57.21 | 2022-2024 | Ova1 |
| Genmab U.S., INC. | $55.54 | 2022-2025 | Tivdak |
| Davol INC. | $53.19 | 2023-2024 | Arista Ah Flexitip |
| Ethicon US, LLC | $50.50 | 2021-2024 | Ethicon |
| Smith+Nephew, INC. | $49.12 | 2023 | Stravix Pl |
| Integra Lifesciences Corporation | $46.88 | 2024 | Duraseal Exact Spinal Sealant System, Cusa Clarity, Codman Hakim |
| Myriad Genetic Laboratories, INC. | $38.72 | 2023-2024 | Myrisk |
| Medical Device Business Services, INC. | $38.69 | 2022-2025 | Enseal |
| Medtronic, INC. | $26.86 | 2022 | |
| Pfizer INC. | $26.19 | 2022-2024 | |
| Coopersurgical, INC. | $25.68 | 2021-2022 | |
| Dilon Technologies, INC. | $21.95 | 2025 | Hemoblast Bellows |
| Clovis Oncology, INC. | $20.78 | 2019 | |
| Immunogen, INC. | $20.78 | 2023 | Elahere |
| Glaxosmithkline, LLC. | $18.32 | 2022 | |
| Renovia INC | $13.86 | 2019 | |
| Novo Nordisk INC | $13.02 | 2019 | |
| Lupin INC. | $12.12 | 2019 | |
| Scynexis, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Pirics listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.